Analysis of amorphous solid dispersions using 2D solid-state NMR and 1H T 1 relaxation measurements

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1667-1691

  Pham, Tran N ^a   Watson, Simon A ^a   Edwards, Andrew J ^a   Chavda, Manisha ^b   Clawson, Jacalyn S ^b   Strohmeier, Mark ^b   Vogt, Frederick G ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Amorphous solid dispersion; double quantum spectroscopy; glass solution; heteronuclear correlation; molecular dispersion; nanosuspension; solid state NMR; spin diffusion

Indexed keywords

CARBON 13; DEXTRAN; DIFLUNISAL; FLUORINE; GLASS; INDOMETACIN; PARACETAMOL; POLYMER; PROTON; SODIUM 23; TELITHROMYCIN; TREHALOSE; VORICONAZOLE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DISPERSION; DRUG STRUCTURE; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE SEPARATION; POLARIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE; X RAY DIFFRACTION;

ACETAMINOPHEN; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DEXTRANS; DOSAGE FORMS; INDOMETHACIN; KETOLIDES; MAGNETIC RESONANCE SPECTROSCOPY; PYRIMIDINES; SOLUBILITY; SUSPENSIONS; TREHALOSE; TRIAZOLES;

EID: 77957743226     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100205g     Document Type: Article

References (105)

1. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249
2. Streubel, A.; Siepmann, J.; Bodmeier, R. Drug delivery to the upper small intestine window using gastroretentive technologies Curr. Opin. Pharmacol. 2006, 6, 501-508
3. Lobenberg, R.; Amidon, G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur. J. Pharm. Biopharm. 2000, 50, 3-12
4. Serajuddin, A. T. M. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 1999, 88, 1058-1066
5. Janssens, S.; Van den Mooter, G. Physical chemistry of solid dispersions J. Pharm. Pharmacol. 2009, 61, 1571-1586
6. Habib, M. J.; Venkataram, S.; Hussain, M. D. Fundamentals of solid dispersions. In Pharmaceutical Solid Dispersion Technology; Habib, M. J., Ed.; Technomic Publishing: Lancaster, PA, 2001; pp 7 - 35.
7. Desai, J.; Alexander, K.; Riga, A. Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release Int. J. Pharm. 2006, 308, 115-123
8. Fawaz, F.; Bonini, F.; Guyot, M.; Bildet, J.; Maury, M.; Lagueny, A. M. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits Int. J. Pharm. 1996, 132, 271-275
9. Torrado, S.; Torrado, S.; Torrado, J. J.; Cadorniga, R. Preparation, dissolution and characterization of albendazole solid dispersions Int. J. Pharm. 1996, 140, 247-250
10. Neervanna, S. Preclinical formulations for discovery and toxicology: Physicochemical challenges Expert Opin. Drug Metab. Toxicol. 2006, 2, 715-731
11. Pignatello, R.; Bucolo, C.; Ferrara, P.; Maltese, A.; Puleo, A.; Puglisi, G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. Sci. 2002, 16, 53-61
12. Pignatello, R.; Ferro, M.; De Guidi, G.; Salemi, G.; Vandelli, M. A.; Guccione, S.; Geppi, M.; Forte, C.; Puglisi, G. Preparation, characterization and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100® and RL100® Int. J. Pharm. 2001, 218, 27-42
13. Chiou, W. L.; Riegelman, S. Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 1971, 60, 1281-1302
14. Rumondor, A. C. F.; Marsac, P. J.; Stanford, L. A.; Taylor, L. S. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture Mol. Pharmaceutics 2009, 6, 1492-1505
15. Rumondor, A. C. F.; Taylor, L. S. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture Mol. Pharmaceutics 2010, 7, 477-490
16. Byrn, S. R.; Pfeiffer, R. R.; Stowell, J. G. Solid-state Chemistry of Drugs; SSCI: West Lafayette, IN, 1999.
17. Bernstein, J. Polymorphism in Molecular Crystals.: Oxford University Press: New York, 2002.
18. Ozeki, T.; Hiroshi, Y.; Kanaya, Y. Application of the solid dispersion method to the controlled release of medicine. IX. Difference in the release of flurbiprofen from solid dispersions with poly(ethylene oxide) and hydroxypropylcellulose and the interaction between medicine and polymers Int. J. Pharm. 1997, 155, 209-217
19. Jachowicz, R.; Nurnberg, E.; Pieszczek, B.; Kluczykowska, B.; Maciejewska, A. Solid dispersion of ketoprofen in pellets Int. J. Pharm. 2000, 206, 13-21
20. de Villiers, M. M.; Wurster, D. E.; Van der Watt, J. G.; Ketkar, A. X-Ray powder diffraction determination of the relative amount of crystalline acetaminophen in solid dispersions with polyvinylpyrrolidone Int. J. Pharm. 1998, 163, 219-224
21. Tantishaiyakul, V.; Kaewnopparat, N.; Ingkatawornwong, S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30 Int. J. Pharm. 1996, 143, 59-66
22. Paudel, A.; Van Humbeeck, J.; Van den Mooter, G. Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in polyvinylpyrrolidone. Mol. Pharmaceutics [Online early access]. DOI: 10.1021/mp100013p. Published online: June 21, 2010.
23. Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. Characterization of amorphous API:polymer mixtures using X-ray powder diffraction J. Pharm. Sci. 2008, 97, 4840-4857
24. Ivanisevic, I.; Bates, S.; Chen, P. Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions J. Pharm. Sci. 2009, 98, 3373-3386
25. Taylor, L. S.; Zografi, G. Spectroscopic characterization of interactions between PVP and indomethacin as amorphous molecular dispersions Pharm. Res. 1997, 14, 1691-1698
26. Trent, J. S.; Scheinbeim, J. I.; Couchman, P. R. Ruthenium tetraoxide staining of polymers for electron microscopy Macromolecules 1983, 16, 589-598
27. Schmidt-Rohr, K.; Spiess, H. W. Multidimentional Solid-State NMR and Polymers: Academic Press: London, 1994.
28. Geppi, M.; Guccione, S. Molecular properties of ibuprofen and its solid dispersions with Eudragit RL100 studied by solid-state nuclear magnetic resonance Pharm. Res. 2005, 22, 1544-1555
29. Mollica, G.; Geppi, M.; Pignatello, R.; Veracini, C. A. Molecular properties of flurbiprofen and its solid dispersions with Eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance Pharm. Res. 2006, 23, 2129-2140
30. Tobyn, M.; Brown, J.; Dennis, A. B.; Fakes, M.; Gao, Q.; Gamble, J.; Khimyak, Y. Z.; McGeorge, G.; Patel, C.; Sinclair, W.; Timmins, P.; Yin, S. Amorphous drug-PVP dispersions: Application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state J. Pharm. Sci. 2009, 98, 3456-3468
31. Schachter, D. M.; Xiong, J.; Tirol, G. C. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly(ethylene oxide) Int. J. Pharm. 2004, 281, 89-101
32. Wulff, M.; Alden, M.; Tegenfeldt, J. Solid-state NMR investigation of indomethacin-cyclodextrin complexes in PEG 6000 carrier Bioconjugate Chem. 2002, 13, 240-248
33. 13C solid state NMR Int. J. Pharm. 2002, 248, 123-129
34. Watanabe, T.; Hasegawa, S.; Wakiyama, N.; Kusai, A.; Senna, M. Comparision between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion Int. J. Pharm. 2003, 250, 283-286
35. Ito, A.; Watanabe, T.; Yada, S.; Hamaura, T.; Nakagami, H.; Higashi, K.; Moribe, K.; Yamamoto, K. Prediction of recrystallization behavior of troglitazone/polyvinylpyrrolidone solid dispersion by solid-state NMR Int. J. Pharm. 2010, 383, 18-23
36. Meier, B. H. Polarization transfer and spin diffusion in solid-state NMR Adv. Magn. Opt. Reson. 1994, 18, 1-116
37. Cheung, T. T. P. Spin diffusion in solids. In The Encyclopedia of NMR; Harris, R. K.; Grant, D. M., Eds.; Wiley: New York, 1996; pp 4518 - 4524.
38. Io, T.; Fukami, T.; Yamamoto, K.; Suzuki, T.; Xu, J.; Tomono, K.; Ramamoorthy, A. Homogeneous nanoparticles to enhance the efficiency of a hydrophobic drug, antihyperlipidemic probucol, characterized by solid-state NMR Mol. Pharmaceutics 2010, 7, 299-305
39. Owusu-Ababio, G. Use of polymers in solid dispersion technology. In Pharmaceutical Solid Dispersion Technology; Habib, M. J., Ed.; Technomic Publishing: Lancaster, PA, 2001; pp 65 - 86.
40. Vogt, F. G.; Clawson, J. S.; Strohmeier, M.; Edwards, A. J.; Pham, T. N.; Watson, S. A. Solid-state NMR analysis of organic cocrystals and complexes Cryst. Growth Des. 2009, 9, 921-937
41. Vogt, F. G.; Vena, J. A.; Chavda, M.; Clawson, J. S.; Strohmeier, M.; Barnett, M. E. Structural analysis of 5-fluorouracil and thymine solid solutions J. Mol. Struct. 2009, 932, 16-30
42. Lubach, J. W.; Xu, D.; Segmuller, B. E.; Munson, E. J. Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability J. Pharm. Sci. 2007, 96, 777-787
43. 1H NMR relaxation times J. Pharm. Sci. 2000, 89, 408-416
44. Forster, A.; Apperly, D.; Hempenstall, J.; Lancaster, R.; Rades, T. Investigation of the physical stability of amorphous drug and drug/polymer melts using variable temperature solid state NMR Pharmazie 2003, 58, 761-762
45. 19F-NMR for assessing the molecular mobility of flufenamic acid in solid dispersions Chem. Pharm. Bull. 2009, 57, 61-64
46. Martinez-Oharriz, M. C.; Rodriguez-Espinosa, C.; Martin, C.; Goni, M. M.; Tros-Ilarduya, M. C.; Sanchez, M. Solid dispersions of diflunisal-PVP: Polymorphic and amorphous states of the drug Drug Dev. Ind. Pharm. 2002, 28, 717-725
47. Metz, G.; Wu, X.; Smith, S. O. Ramped-amplitude cross-polarization in magic-angle spinning NMR J. Magn. Reson. A 1994, 110, 219-227
48. Antzutkin, O. N. Sideband manipulation in magic-angle spinning NMR Prog. Nucl. Magn. Reson. Spectrosc. 1999, 35, 203-266
49. Fung, B. M.; Khitrin, A. K.; Ermolaev, K. An improved broadband decoupling sequence for liquid crystals and powders J. Magn. Reson. 2000, 142, 97-101
50. Hodgkinson, P. Heteronuclear decoupling in the NMR of solids Prog. Nucl. Magn. Reson. Spectrosc. 2005, 46, 197-222
51. Opella, S. J.; Frey, M. H. Selection of non-protonated carbon resonances in solid-state NMR J. Am. Chem. Soc. 1979, 101, 5854-5856
52. 13C chemical shifts in solids J. Magn. Reson. 1982, 48, 35-54
53. Harris, R. K.; Becker, E. D.; Cabral de Menezes, S. M.; Goodfellow, R.; Granger, P. NMR nomenclature. Nuclear spin properties and conventions for chemical shifts (IUPAC recommendations 2001) Pure Appl. Chem. 2001, 73, 1795-1818
54. Sagnowski, S. F.; Aravamudhan, S.; Haeberlen, U. Wide-line and high-resolution proton magnetic resonance in single crystals of malonic acid J. Magn. Reson. 1977, 28, 271-288
55. 2H MAS NMR spectra J. Magn. Reson. 1991, 92, 443-453
56. 13C CP/MAS NMR spectroscopy and direct exponential curve resolution algorithm J. Am. Chem. Soc. 1999, 121, 11554-11557
57. Massiot, D.; Fayon, F.; Capron, M.; King, I.; Le Calve, S.; Alonso, B.; Durand, J. O.; Bujoli, B.; Gan, Z.; Hoatson, G. Modelling one- and two-dimensional solid-state NMR spectra Magn. Reson. Chem. 2002, 40, 70-76
58. Bevington, P. R.; Robinson, D. K. Data reduction and error analysis for the physical sciences, 3rd ed.; McGraw-Hill: New York, 2003; pp 142 - 163.
59. Feike, M.; Demco, D. E.; Graf, R.; Gottwald, J.; Hafner, S.; Spiess, H. W. Broadband multiple-quantum NMR spectroscopy J. Magn. Reson. A 1996, 122, 214-221
60. 13C NMR heteronuclear dipolar-correlation spectroscopy of solids with frequency-switched Lee-Goldburg homonuclear decoupling J. Magn. Reson. 1997, 124, 516-519
61. 13C) distances in high speed MAS NMR J. Am. Chem. Soc. 2000, 122, 3465-3472
62. 13C RF irradiation in nuclear magnetic resonance of rotating solids J. Chem. Phys. 2003, 118, 2325-2341
63. Amoureux, J.-P.; Fernandez, C.; Steuernagel, S. Z filtering in MQMAS NMR J. Magn. Reson. A 1996, 123, 116-118
64. Rocha, J.; Morais, C. M.; Fernandez, C. Progress in multiple-quantum magic-angle-spinning NMR spectroscopy Top. Cur. Chem. 2005, 246, 141-194
65. Haisa, M.; Kashino, S.; Kawai, R.; Maeda, H. The monoclinic form of p-hydroxyacetanilide Acta Crystallogr. 1976, B32, 1283-1285
66. Moynihan, H. A.; O'Hare, I. P. Spectroscopic characterization of the monoclinic and orthorhombic forms of paracetamol Int. J. Pharm. 2002, 247, 179-185
67. Nichols, G.; Frampton, C. S. Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution J. Pharm. Sci. 1998, 87, 684-693
68. Zhou, D. H.; Rienstra, C. M. Rapid analysis of organic compounds by proton-detected heteronuclear correlation NMR spectroscopy with 40 kHz magic-angle spinning Angew. Chem., Int. Ed. 2008, 47, 7328-7331
69. Wilson, C. C.; Shankland, N.; Florence, A. J.; Frampton, C. S. Single-crystal neutron diffraction of bio-active small molecules Phys. B (Amsterdam, Neth.) 1997, 234-236
70. 13C CPMAS NMR study of poly(3-octylthiophene)/poly(phenylene oxide) Macromolecules 1993, 26, 6517-6524
71. McBrierty, V. J.; Douglass, D. C. Recent advances in the NMR of solid polymers J. Polym. Sci.: Macromol. Rev. 1981, 16, 295-366
72. 13C NMR spectroscopy Macromolecules 1988, 21, 1282-1291
73. Wen, H.; Morris, K. R.; Park, K. Study on the interactions between polyvinylpyrrolidone (PVP) and acetaminophen crystals: Partial dissolution pattern change J. Pharm. Sci. 2005, 94, 2166-2174
74. Yoshioka, M.; Hancock, B. C.; Zografi, G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates J. Pharm. Sci. 1995, 84, 983-986
75. Guilbaud, J. B.; Cummings, L.; Khimyak, Y. Encapsulation of indomethacin in PVP: solid-state NMR studies Macromol. Symp. 2007, 251, 41-46
76. Levitt, M. H. Spin dynamics: Basics of nuclear magnetic resonance; John Wiley & Sons: Chichester, 2001; pp 513 - 538.
77. Cox, P. J.; Manson, P. L. γ-Indomethacin at 120 K Acta Crystallogr. 2003, E59 o986-o988
78. 13C NMR study of indomethacin polymorphism Int. J. Pharm. 2006, 318, 146-153
79. Apperley, D. C.; Forster, A. H.; Fournier, R.; Harris, R. K.; Hodgkinson, P.; Lancaster, R. W.; Rades, T. Characterisation of indomethacin and nifedipine using variable-temperature solid-state NMR Magn. Reson. Chem. 2005, 43, 881-892
80. Vogt, F. G.; Katrincic, L. M.; Long, S. T.; Mueller, R. L.; Carlton, R. A.; Sun, Y. T.; Johnson, M. N.; Copley, R. C. B.; Light, M. E. Enantiotropically-related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4- (methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid. Crystal structures and multinuclear solid-state NMR J. Pharm. Sci. 2008, 97, 4756-4782
81. Savolainen, M.; Heinz, A.; Strachan, C.; Gordon, K. C.; Yliruusi, J.; Rades, T.; Sandler, N. Screening for differences in the amorphous state of indomethacin using multivariate visualization Eur. J. Pharm. Sci. 2007, 30, 113-123
82. Vanderhart, D. L.; McFadden, G. B. Some perspectives on the interpretation of proton NMR spin diffusion data in terms of polymer morphologies Solid State Nucl. Magn. Reson. 1996, 7, 45-66
83. Demco, D. E.; Johansson, A.; Tegenfeldt, J. Proton spin diffusion for spatial heterogeneity and morphology investigations of polymers Solid State Nucl. Magn. Reson. 1995, 4, 13-38
84. Cherry, B. R.; Fujimoto, C. H.; Cornelius, C. J.; Alam, T. M. Investigation of domain size in polymer membranes using double-quantum-filtered spin diffusion magic angle spinning NMR Macromolecules 2005, 38, 1201-1206
85. Marjanski, M.; Srinivasarao, M.; Mirau, P. A. Solid-state multiple proton nuclear magnetic resonance (NMR) characterization of self-assembling polymer films Solid State Nucl. Magn. Reson. 1998, 12, 113-118
86. 13C NMR detection Magn. Reson. Chem. 1990, 28, 3-9
87. 15N spin diffusion rate in solid-state NMR of totally enriched proteins: The magic angle spinning frequency effect J. Magn. Reson. 2006, 182, 339-342
88. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643
89. Steelman, S. L.; Cirillo, V. J.; Tempero, K. F. The chemistry, pharmacology and clinical pharmacology of diflunisal Curr. Med. Res. Opin. 1978, 5, 506-514
90. Cross, W. I.; Blagden, N.; Davey, R. J.; Pritchard, R. G.; Neumann, M. A.; Roberts, R. J.; Rowe, R. C. A whole output strategy for polymorph screening: Combining crystal structure prediction, graph set analysis, and targeted crystallization experiments in the case of diflunisal Cryst. Growth Des. 2003, 3, 151-158
91. Martínez-Ohárriz, C.; Martín, C.; Goñi, M. M.; Rodríguez-Espinosa, C.; Tros De Ilarduya-Apaolaza, M. C.; Sánchez, M. Polymorphism of diflunisal: Isolation and solid-state characteristics of a new crystal form J. Pharm. Sci. 1994, 83, 174-177
92. Perlovich, G. L.; Hansen, L. K.; Bauer-Brandl, A. Interrelation between thermochemical and structural data of polymorphs exemplified by diflunisal J. Pharm. Sci. 2002, 91, 1036-45
93. Cotton, M. L.; Hux, R. A. Diflunisal Anal. Profiles Drug Subst. 1985, 14, 491-526
94. Yamamura, S.; Gotoh, H.; Sakamoto, Y.; Momose, Y. Physicochemical properties of amorphous salt of cimetidine and diflunisal system Int. J. Pharm. 2002, 241, 213-221
95. Hagaman, E. W.; Burns, J. H. The determination of local structure in organofluorides using fluorine-19 carbon-13 dipolar coupling Fuel 1993, 72, 1239-1243
96. Ackermann, G.; Rodloff, A. C. Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide J. Antimicrob. Chemother. 2003, 51, 497-511
97. Evrard-Todeschi, N.; Gharbi-Benarous, J.; Gaillet, C.; Verdier, L.; Bertho, G.; Lang, C.; Parent, A.; Girault, J.-P. Conformations in solution and bound to bacterial ribosomes of ketolides, HMR 3647 (telithromycin) and RU 72366: A new class of highly potent antibacterials Bioorg. Med. Chem. 2000, 8, 1579-1597
98. Ludescher, J.; Griesser, U.; Langes, C. Amorphous telithromycin compound. PCT Int. Appl. EP2007/000036, Nov 13, 2008.
99. de Waard, H.; Hinrichs, W. L. J.; Visser, M. R.; Bologna, C.; Frijlink, H. W. Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated Int. J. Pharm. 2008, 349, 66-73
100. Morris, K. R.; Knipp, G. T.; Serajuddin, A. T. M. Structural properties of polyethylene glycol-polysorbate 80 mixture, a solid dispersion vehicle J. Pharm. Sci. 1992, 81, 1185-1188
101. Mura, P.; Moyano, J. R.; Gonzalez-Rodriguez, M. L.; Rabasco-Alvarez, A. M.; Cirri, M.; Maestrelli, F. Characterization and dissolution properties of ketoprofen in binary and ternary solid dispersions with polyethylene glycol and surfactants Drug Dev. Ind. Pharm. 2005, 31, 425-434
102. Ghebremeskel, A. N.; Vemavarapu, C.; Lodaya, M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability Int. J. Pharm. 2007, 328, 119-129
103. Dickinson, R. P.; Bell, A. S.; Hitchcock, S.; Narayanaswami, S.; Richardson, K.; Troke, P. F. Novel antifungal 2-aryl-1-(1 H -1,2,4-triazol-1-yl) butan-2-ol derivates with high activity against Aspergillus fumigatus Bioorg. Med. Chem. Lett. 1996, 16, 2031-2036
104. Ravikumar, K.; Sridhar, B.; Prasad, K. D.; Rao, A. K. S. B. Voriconazole, an antifungal drug Acta Crystallogr. 2007, 63 o565-o567
105. 23Na NMR J. Mol. Struct. 1999, 508, 97-102